Slide 1: Elevating the World's Wellbeing Q4 2022
Elevating the World’s Wellbeing Q4 2022 (1 January 2022 - 31 December 2022) Webcast presentation | February 28th 10:00 CET Q4
Slide 2: Forward-looking statement
Forward-looking statement This presentation contains certain forward-looking statements and opinions. Forward-looking statements are statements that do not relate to historical facts and events and such statements and opinions pertaining to the future that, for example, contain wording such as "beli
Slide 3: Agenda
Agenda Q4 in short Business update Financial results Strategy and outlook Q&A Henrik Molin CEO & co-founder Charlotte Goodwin CFO Q1 Q2 Q3 Q4 3
Slide 4: Q4 in short
Q4 in short Q1 Q2 Q3 Q4 4
Slide 5: Completing the year with strong revenue growth and bottom line EBITDA
Completing the year with strong 57% 27% 31% revenue growth and bottom Adjusted EBITDA line EBITDA, having established Q4 YTD 2022 revenue growth Q4 YTD 2022 proforma YTD increased to strong foundations to revenue growth €3.4m accelerate growth for FY2023 Quarterly progress Wellness Lifecare - Finali
Slide 6: Business updates
Business updates > Physitrack a @
Slide 7: Our two business lines position us to capitalize on digital healthcare demand
Our two business lines has us well-positioned to capitalize on increasing digital healthcare demand and corporate wellbeing challenges Physitrack PLC, founded in 2012, is a global B2B digital healthcare provider, focused on providing technology to Care Providers and providing solutions to Corporates
Slide 8: Current state of play
Current state of play Revenue evolution EUR 13.7m (EURm) Wellness EUR 4.3m Physitrack was born out of Lifecare a desire to create a more EUR 5.3m Lifecare effective way to prescribe 89% exercise programs, as well Organic revenue EUR 9.4m as improve patient CAGR outcomes and reduce Selected to Apple’
Slide 9: The world leader in Lifecare technology
The world leader in Lifecare technology. Supporting the patient journey every step of the way with a uniquely comprehensive solution. to the right care from Q1 Q2 Q3 Q4 9
Slide 10: Lifecare quarterly developments
Lifecare quarterly developments Rationalisation of division 7% growth in license numbers within our Lifecare • Profitability focus has resulted in finding efficiencies and synergies in the division 54,000 including: • Rationalisation of operating structure – merging Tanila Holding and Physiotools 53
Slide 11: One platform. All areas of Wellbeing.
One platform. All areas of Wellbeing. Empowering employee wellbeing through data, insight and action. PREVENTION & PREVENTION & POST-ACUTE, ANALYSIS & WELLNESS WELLNESS POST-OP, CHRONIC FOLLOW-UP & ASSESSMENT ANALYSIS (PHYSICAL) (EMOTIONAL) CARE PROVISION Testing and assessment Technology-led exerci
Slide 12: Wellness quarterly developments
Wellness quarterly developments Growth, Wellness segment Growth, Wellness segment excluding Record setting performance Fysiotest 4.5 3.50 • Q4 in the Wellness division went from strength to strength building on the 4.0 success of previous quarters. Notable milestones within the division include: 3.0
Slide 13: Product led growth
Product led growth Launched LinkedIn retargeting campaigns to leverage organic social following Perfect for SME businesses to support their employee wellbeing Launched new Google Ads display retargeting campaigns SME businesses account for 99% of businesses in the UK alone Q2 Q3
Slide 14: Workplace Health Report
Workplace Health Report 1,300 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4
Slide 15: Integration to Create a Seamless Experience
One platform. All areas of Wellbeing. Integration to Create a Seamless Experience Create a single point of access for all health and EAP wellbeing services across your organisation PRIVATE MEDICAL Content is tailored to your existing services withing the platform INSURANCE PHYSIOTHERAPY Customised c
Slide 16: Champion Health in action – the case with Strata
Champion Health in action – the case with Strata Looking to improve employee wellbeing • Seeing the strain their people were under, Strata wanted to make a difference and support their people when they needed it. -68% • Partnering with Champion Health provided Strata’s leadership team with a dynamic
Slide 17: Financial Results
Financial Results Q1 Q2 Q3 Q4 17
Slide 18: Q4 Financial Highlights
Q 1 2 Q4 Financial Highlights 12 month revenue 12 Month EBITDA 57% 186% €12.5m (Q4 2021: €8.0m) €2.5m (Q4 2021: €0.9m) Operating cashflow 12 month proforma 27% 103% revenue growth €1.5m (Q4 2021: €0.7m) 12 month adjusted EBITDA 12 month adjusted EBITDA margin 31% €3.4m (Q4 2021: €2.6m) 28% (Q4 2021:
Slide 19: Maintaining revenue growth
Q 1 2 Maintaining revenue growth In-line with medium term growth targets Group Revenue Lifecare revenue growth Wellness revenue growth 2.5 4.0 2.5 5% 3.5 20% 2.0 2.0 3.0 38% 2.5 1.5 1.5 2.0 55% 1.0 1.5 1.0 1.0 0.5 0.5 0.5 - - - Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2021
Slide 20: EBITDA
Q 1 2 EBITDA 4.0 Strong growth 3.5 31% 3.0 €0.9M 2.5 €'million 2.0 €2.6M €1.7M 186% €3.4M 1.5 ADJUSTED EBITDA €2.5M Margin ADJUSTED EBITDA 1.0 33% Margin 28% 0.5 €0.9m - 12 MONTHS 2021 EBITDA Adjusting it ems* 12MONTHS 2021 Adjusted 12 MONTHS 2022 EBITDA Adjusting it ems* 12 MONTHS 2022 Adjusted EBI
Slide 21: Adjusted EBITDA
Q 1 2 Adjusted EBITDA 4.0 3.5 7% Adjusted EBITDA by division 3.0 0.8 49% 4.3 2.5 Q4 YTD 2022 2% 0.1 0.8 0.9 2.0 (0.9) 1.5 0.7 48% 3.3 0.9 1.0 Q4 YTD 2021 7% 0.1 0.6 (0.8) 0.5 0.8 0.5 (2.0) (1.0) - 1.0 2.0 3.0 4.0 5.0 - Lifecare Wel lness Group 2021 ADJ EBITDA 2022 ADJ EBITDA Q1 Q2 Q3 Q4 21 Q1 Q2 Q3
Slide 22: Cashflow
Q 1 2 Cashflow 18.0 (0.6) 16.0 (0.1) 3.4 14.0 (4.5) 12.0 10.0 8.0 (6.9) 13.3 6.0 4.0 €4.6m undrawn on ( 3.4 ) facility 4.6 2.0 (1.4) 0.8 (0.2) 0.6 - 1 Jan 2022 Opening Adjusted EBITDA Working capital Interest expense Purchase of Acqui stions net of Deferred M&A costs Drawdown of Fx 31 December 2022
Slide 23: Quarterly reduction in cash burn
Q 1 2 Quarterly reduction in Cash burn (1) - Q1 Q2 Q3 Q4 (0.2) (0.4) (0.6) (0.8) (1.0) (1.2) (1) Cash burn is defined as net cash from operating activities, less purchase of intangible assets and property, plant and equipment 23 Q1 Q2 Q3 Q4
Slide 24: Balance Sheet
Q 1 2 Balance Sheet Net assets position strengthened from goodwill and intangibles recognized on acquisitions 31 December 2022 31 December 2021 Euros '000 Goodwill, intangibles and PPE 37,738 17,221 Cash and cash equivalents 578 13,325 Borrowings (832) (1) Trade and other receivables 2,950 1,666 Inv
Slide 25: Strategy and outlook
Strategy and outlook Q1 Q2 Q3 Q4 25
Slide 26: Financial goals – What we aim for
Financial goals – What we aim for Top-line growth Profit margins Value creation/distribution Physitrack aims to achieve annual Physitrack targets an EBITDA margin Physitrack aims to reinvest profits organic sales growth exceeding 30% of 40-45% in the medium term, with and cash flows in organic growt
Slide 27: A robust business model, able to withstand headwinds
A robust business model, able to withstand headwinds Balanced portfolio Our geographical diversity and varied revenue streams make the business robust - dramatic changes in the world do not necessarily affect all parts of our business Profitable growth is part of our DNA Our organisation is cost opt
Slide 28: Executing a well-defined growth plan combining organic and inorganic initiatives
Executing a well-defined growth plan combining organic and inorganic initiatives Planning to build a global powerhouse in the remote physical care space through well-defined, tangible organic and inorganic growth objectives 3 M&A initiative 2 Continue strong M&A integration to Organic growth levers
Slide 29: Q&A
Q&A Q1 Q2 Q3 Q4 29